MD20140101A2 - Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer - Google Patents

Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer

Info

Publication number
MD20140101A2
MD20140101A2 MDA20140101A MD20140101A MD20140101A2 MD 20140101 A2 MD20140101 A2 MD 20140101A2 MD A20140101 A MDA20140101 A MD A20140101A MD 20140101 A MD20140101 A MD 20140101A MD 20140101 A2 MD20140101 A2 MD 20140101A2
Authority
MD
Moldova
Prior art keywords
clusterin
inhibitor
egfr
cancer
cancer cells
Prior art date
Application number
MDA20140101A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Джиллс Бернард ТРЕМБЛИ
Элизабет ВИАУ
Марио ФИЛИОН
Original Assignee
Alethia Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics Inc. filed Critical Alethia Biotherapeutics Inc.
Priority claimed from PCT/CA2013/000167 external-priority patent/WO2013123588A1/en
Publication of MD20140101A2 publication Critical patent/MD20140101A2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to medicine, particularly to oncology, and can be used to treat cancer.According to the invention, epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in the treatment of cancer are thus provided in the present invention.
MDA20140101A 2013-02-22 2013-02-22 Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer MD20140101A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361601786P 2013-02-22 2013-02-22
PCT/CA2013/000167 WO2013123588A1 (en) 2012-02-22 2013-02-22 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Publications (1)

Publication Number Publication Date
MD20140101A2 true MD20140101A2 (en) 2015-02-28

Family

ID=52580519

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140101A MD20140101A2 (en) 2013-02-22 2013-02-22 Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer

Country Status (1)

Country Link
MD (1) MD20140101A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056054A1 (en) * 2004-11-23 2006-06-01 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056054A1 (en) * 2004-11-23 2006-06-01 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity

Similar Documents

Publication Publication Date Title
MX2021002728A (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors.
MX2019004193A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer.
MX2017005553A (en) Combination therapy for cancer.
PH12015502339A1 (en) Arylquinazolines
BR112014020756A2 (en) co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
NZ628314A (en) Cd47 antibodies and methods of use thereof
PH12018502570A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
NZ631197A (en) Anti sez6 antibodies and methods of use
CA2886946C (en) Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour
EA201590747A1 (en) METHODS OF TREATMENT USING ADENOVIRUS
MX2017006015A (en) Apilimod for use in the treatment of renal cancer.
PH12016500580A1 (en) Conjugated antibodies against ly75 for the treatment of cancer
PH12016500753B1 (en) Antibodies specific to fcrn
MX2017000142A (en) Mesenchymal stromal cells for treating sepsis.
MX2016009655A (en) Novel methods for treating cancer.
IN2014MN02114A (en)
MX2019004940A (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody.
MX2016002938A (en) Predicting breast cancer recurrence.
MX2014004991A (en) Therapeutic combinations and methods of treating melanoma.
MX2016002720A (en) Method for improving antibody stability.
EA201992875A1 (en) T-CELLS WITH REDUCED SURFACE FUCHOSILING AND METHODS FOR PRODUCING AND USING THEM
TR201909632T4 (en) Nmda antagonist prodrugs.
MD20140101A2 (en) Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
GB201212690D0 (en) Materials and methods for treating pten mutated or deficient cancer
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Legal Events

Date Code Title Description
FC9A Refusal of application (patent for invention)